金融界2025年8月24日消息，景顺长城国企价值混合A(018294) 最新净值1.3787元，该基金近一周收益 率-0.04%，近3个月收益率11.07%，今年来收益率14.41%。 该基金股票持仓前十分别为：紫金矿业、中国移动、神火股份、腾讯控股、中国海洋石油、川仪股份、 国药控股、株冶集团、云铝股份、中国中车。前十持仓占比合计52.32%。 来源：金融界 景顺长城国企价值混合A基金成立于2023年5月30日，基金经理邹立虎，截至2025年6月30日，景顺长城 国企价值混合A规模2.95亿元。 ...

Performance Summary - China Petroleum & Chemical Corporation (00386.HK) reported a revenue of 1,409.05 billion yuan, a decrease of 10.6% year-on-year, and a net profit of 21.483 billion yuan, down 39.8% year-on-year [2] - Kuaishou Technology (01024.HK) achieved a revenue of 67.654 billion yuan, an increase of 12.04% year-on-year, with a net profit of 8.9 billion yuan, up 9.9% year-on-year [2] - China National Pharmaceutical Group (01099.HK) recorded a revenue of 36.363 billion yuan, a decrease of 1.48% year-on-year, and a net profit of 295 million yuan, an increase of 1.02% year-on-year [2] - Miniso Group (09896.HK) reported a revenue of 9.393 billion yuan, a growth of 21.1% year-on-year, but a net profit of 906 million yuan, down 22.6% year-on-year [2] - Tuhu (09690.HK) had a revenue of 7.9 billion yuan, an increase of 10.5% year-on-year, with an adjusted net profit of 410 million yuan, up 14.6% year-on-year, and the number of stores increased to 7,205 [2] - Bilibili Inc. (09626.HK) reported a second-quarter revenue of 7.338 billion yuan, an increase of 19.76% year-on-year, and a net profit of 219 million yuan, turning from a loss of 609 million yuan in the same period last year [2] - Zaitong (00062.HK) achieved a revenue of 4.226 billion HKD, an increase of 3.98% year-on-year, and a net profit of 190 million HKD, up 57.94% year-on-year [2] - Xincheng Power (01148.HK) reported a revenue of 2.804 billion yuan, an increase of 7.06% year-on-year, but a net profit of 16.49 million yuan, down 25.49% year-on-year [2] - Fourth Paradigm (06682.HK) achieved a revenue of 2.626 billion yuan, an increase of 40.71% year-on-year, with an adjusted net loss of 44 million yuan, narrowing by approximately 71.2% from a loss of 152 million yuan in the same period last year [2] - Meilian Group (01200.HK) reported a revenue of 2.518 billion HKD, a decrease of 24.1% year-on-year, and a net profit of 151 million HKD, down 13% year-on-year [2] - Baisheng Group (03368.HK) achieved a revenue of 1.963 billion yuan, an increase of 0.93% year-on-year, and a net profit of 22.468 million yuan, turning from a loss of 18.641 million yuan in the same period last year [2] - Yuexiu Services (06626.HK) reported a revenue of approximately 1.962 billion yuan, a slight increase of 0.09% year-on-year, with a net profit of approximately 240 million yuan [2] - Yika (09923.HK) achieved a revenue of 1.64 billion yuan, an increase of 4% year-on-year, and a net profit of 43.075 million yuan, up 36.2% year-on-year [2] - Gaoweidianzi (01415.HK) reported a revenue of 1.36 billion USD, an increase of 132.2% year-on-year, with a net profit of 67.398 million USD, up approximately 320% year-on-year [2] - BOC Aviation (02588.HK) achieved a revenue of 1.242 billion USD, an increase of 6% year-on-year, but a net profit of 342 million USD, down 26% year-on-year [2] - Jiuxing Holdings (01836.HK) reported a revenue of 775 million USD, an increase of 0.7% year-on-year, but a net profit of 78.633 million USD, down 14.5% year-on-year [2] - Sinopec Kantons Holdings (00934.HK) reported a revenue of approximately 307 million HKD, a decrease of 7.2% year-on-year, and a net profit of approximately 563 million HKD, down 17.8% year-on-year [2] - Great Wall Holdings (00583.HK) issued a profit warning, expecting a mid-term net loss of 266 million to 294 million HKD, a significant shift from profit to loss [2] Company News - Shengye (06069.HK) has initiated a global strategic layout to build an AI + international supply chain technology platform [2] - Yuan Zheng Technology (02488.HK) plans to develop a strategic layout for equipment assetization and related RWA applications [2] - Oconview Biosciences (01477.HK) announced that the second Phase III clinical trial of OT-301 has reached its primary endpoint [2] Buyback Activities - Tencent Holdings (00700.HK) repurchased 928,000 shares at a cost of 551 million HKD, with a buyback price ranging from 590 to 597 HKD [2] - HSBC Holdings (00005.HK) repurchased approximately 1.33 million shares at a cost of about 132 million HKD, with a buyback price ranging from 98.6 to 99.55 HKD [2] - Techtronic Industries (00669.HK) repurchased approximately 25,000 shares at a cost of about 25.085 million HKD, with a buyback price ranging from 99.5 to 101.6 HKD [2] - Hang Seng Bank (00011.HK) repurchased 200,000 shares at a cost of 22.4935 million HKD, with a buyback price ranging from 111.8 to 112.8 HKD [2]

Group 1 - The core viewpoint of the article highlights the financial performance of China National Pharmaceutical Group Corporation (国药控股) for the six months ending June 30, 2025, indicating a slight decline in revenue and operating profit, while showing a modest increase in comprehensive income attributable to the parent company [1] Group 2 - The company reported operating revenue of 36.363 billion RMB, representing a year-on-year decrease of 1.48% [1] - Operating profit was recorded at 684 million RMB, reflecting a year-on-year decline of 8.28% [1] - Comprehensive income attributable to the parent company was 295 million RMB, which is a year-on-year increase of 1.02% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 1 國藥器械之合併財務報表之主要未經審核財務數據 單位：元 幣種：人民幣 | | | | 本報告期 | | --- | --- | --- | --- | | | 本報告期 | 上年同期 | 比上年同期增減 | | 營業收入 | 36,362,746,042.44 | 36,908,522,536.26 | -1.48% | | 營業利潤 | 684,176,599.68 | 745,979,066.39 | -8.28% | | 歸屬於母公司所有者的 綜合收益總額 | 294,606,310.11 | 291,632,700.32 | 1.02% | | 經營活動產生的現金流 | -2,481,582,321.54 | -7,726,076,201.83 | -67.88% | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 中國醫療器械有限公司 2025 年半年度報告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 茲載列國藥控股股份有限公司旗下一間附屬公司，中國醫療器械有限公司於 2025 年 8 月 21 日 於中國貨幣網及上海清算所網站刊發的《中國醫療器械有限公司 2025 年半年度報告》，僅供參 閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 21 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、 祖敬 先生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、 吳德龍 先生、俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 中国医疗器械有限公司 - 3 - 1 ...

Group 1 - The core viewpoint of the article is that China National Pharmaceutical Group (国药控股) reported its subsidiary China National Pharmaceutical Co., Ltd. (国药股份) financial performance for the first half of 2025, showing a slight increase in revenue but a decline in net profit [1] - The operating revenue for the first half of 2025 was approximately 25.634 billion yuan, representing a year-on-year growth of 3.54% [1] - The net profit attributable to shareholders of the listed company was approximately 949 million yuan, reflecting a year-on-year decrease of 5.19% [1] - The basic earnings per share were reported at 1.2572 yuan [1]

公告 國藥股份截至 2025 年 6 月 30 日止六個月之 主要未經審核會計數據和財務指標 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.09 條及證券及期貨條例（香港法例第 571 章）第 XIVA 部刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 茲提述國藥控股股份有限公司（「本公司」）於 2025 年 8 月 20 日刊發之海外監管公告（「該公 告」），内容有關本公司附屬公司國藥集團藥業股份有限公司（「國藥股份」，其 A 股於上海證 券交易所上市（股票代碼：600511））之 2025 年半年度報告。 本公司董事會謹此提醒股東及公眾投資者注意以下於該公告內載列之國藥股份截至 2025 年 6 月 30 日止六個月（「報告期」）之主要未經審核會計數據和財務指標。 單位：元 幣種：人民幣 本报告期末比 | | 本報告期末 | 上年度末 | 上年度末增减 | (%) | | --- | --- | --- | --- | --- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 國藥集團藥業股份有限公司 2025 年半年度報告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 茲載列國藥控股股份有限公司旗下一間 A 股於上海證券交易所上市的附屬公司，國藥集團藥業 股份有限公司，於 2025 年 8 月 20 日於上海證券交易所網站刊發的《國藥集團藥業股份有限公 司 2025 年半年度報告》，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 20 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 国药 ...

行业主要上市公司：国药控股(01099.HK);上海医药(601607.SH);华润医药(03320.HK);九州通(600998.SH);南京医药(600713.SH);华东医药(000963.SZ);英特集团(000411.SZ) 批发模式中第三终端受互联网医院青睐 批发模式即分销模式，是指批量将药品和医疗器械销售给直接接触消费者的最后环节，包括医疗机构、零售药店、基层医疗机构等或下游分销商。根据销售对象的不同批发模式可进一步区分为以 零售模式规模小但毛利率高 零售模式是指零售药店从医药制造企业或其他医药流通企业购进医药产品后，将其销售给个人消费者以赚取进销差价的模式。相较于批发模式，零售模式的规模更小，但毛利率更高。零售模式具 医药流通行业主要商业模式可分为三类 医药商业是医药行业的子行业之一，是专门从事医药商品经营活动的独立经济分支，主要负责药品在市场上的流通。医药流通行业主要商业模式可分为批发模式、零售模式和各类新型流通模式三 第三方医药冷链物流优势明显 "十四五"时期，药品流通行业需构建现代智慧医药供应链服务新体系，完善行业标准着重提升网络化、规模化、专业化水平使医药物流网络布局更加合理仓储运输全 ...

批发模式中第三终端受互联网医院青睐 转自：前瞻产业研究院 行业主要上市公司：国药控股(01099.HK);上海医药(601607.SH);华润医药(03320.HK);九州通 (600998.SH);南京医药(600713.SH);华东医药(000963.SZ);英特集团（维权）(000411.SZ)等 医药流通行业主要商业模式可分为三类 医药商业是医药行业的子行业之一，是专门从事医药商品经营活动的独立经济分支，主要负责药品在市 场上的流通。医药流通行业主要商业模式可分为批发模式、零售模式和各类新型流通模式三类。批发毛 利率较低其中又分为纯销、快批和调拨等;零售毛利率较高药品零售企业一般就是所谓的零售药店是直 接面对最终消费者患者的商品流通环节也是药品流通的最终环节。 批发模式即分销模式，是指批量将药品和医疗器械销售给直接接触消费者的最后环节，包括医疗机构、 零售药店、基层医疗机构等或下游分销商。根据销售对象的不同批发模式可进一步区分为以下几类：医 院直销：商业调拨、第三终端。此外由于渠道下沉、分散等特点，第三终端目前也是各互联网医药企业 积极布局的市场。 零售模式规模小但毛利率高 零售模式是指零售药店从医药 ...